Equities Analysts Issue Forecasts for Travere Therapeutics, Inc.’s Q2 2022 Earnings (NASDAQ:TVTX)

Travere Therapeutics, Inc. (NASDAQ:TVTXGet Rating) – Investment analysts at Jefferies Financial Group issued their Q2 2022 earnings per share estimates for shares of Travere Therapeutics in a report released on Monday, April 25th. Jefferies Financial Group analyst M. Raycroft forecasts that the company will post earnings of ($0.92) per share for the quarter. Jefferies Financial Group also issued estimates for Travere Therapeutics’ Q3 2022 earnings at ($0.81) EPS, Q4 2022 earnings at ($0.72) EPS and FY2026 earnings at $2.40 EPS.

Travere Therapeutics (NASDAQ:TVTXGet Rating) last announced its quarterly earnings results on Thursday, February 24th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.12). The firm had revenue of $57.25 million during the quarter, compared to the consensus estimate of $56.40 million. Travere Therapeutics had a negative return on equity of 55.22% and a negative net margin of 79.16%. Travere Therapeutics’s revenue was up 12.3% on a year-over-year basis. During the same period last year, the business earned ($2.37) EPS.

Other equities research analysts have also issued research reports about the stock. Piper Sandler assumed coverage on shares of Travere Therapeutics in a report on Wednesday, March 30th. They issued an “overweight” rating and a $42.00 price target on the stock. Zacks Investment Research lowered shares of Travere Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, April 20th. Finally, HC Wainwright assumed coverage on shares of Travere Therapeutics in a research note on Monday, February 28th. They set a “buy” rating and a $45.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $34.11.

Shares of Travere Therapeutics stock opened at $26.54 on Wednesday. The firm has a market cap of $1.69 billion, a PE ratio of -8.76 and a beta of 0.74. Travere Therapeutics has a 12-month low of $12.75 and a 12-month high of $31.65. The company has a quick ratio of 4.64, a current ratio of 4.70 and a debt-to-equity ratio of 0.75. The company’s fifty day simple moving average is $26.85 and its two-hundred day simple moving average is $27.66.

Several large investors have recently modified their holdings of TVTX. Advisor Group Holdings Inc. boosted its position in shares of Travere Therapeutics by 1,448.0% during the third quarter. Advisor Group Holdings Inc. now owns 1,161 shares of the company’s stock worth $28,000 after acquiring an additional 1,086 shares during the last quarter. Lindbrook Capital LLC bought a new position in shares of Travere Therapeutics during the third quarter worth $36,000. Royal Bank of Canada boosted its position in shares of Travere Therapeutics by 132.7% during the second quarter. Royal Bank of Canada now owns 4,053 shares of the company’s stock worth $59,000 after acquiring an additional 2,311 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Travere Therapeutics by 50.9% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,860 shares of the company’s stock worth $134,000 after acquiring an additional 1,640 shares during the last quarter. Finally, Teacher Retirement System of Texas bought a new position in shares of Travere Therapeutics during the third quarter worth $202,000.

In other Travere Therapeutics news, insider Peter Heerma sold 1,125 shares of the company’s stock in a transaction that occurred on Monday, January 31st. The shares were sold at an average price of $27.40, for a total value of $30,825.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Laura Clague sold 1,238 shares of the company’s stock in a transaction on Monday, January 31st. The stock was sold at an average price of $27.40, for a total transaction of $33,921.20. The disclosure for this sale can be found here. Insiders sold 9,324 shares of company stock valued at $254,767 over the last ninety days. Corporate insiders own 4.31% of the company’s stock.

Travere Therapeutics Company Profile (Get Rating)

Travere Therapeutics, Inc, a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.

Read More

Earnings History and Estimates for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.